Protalix BioTherapeutics Announces Closing of Public Offering and Exercise of …

Prior to the closing, the underwriters exercised, in full, their over-allotment option to purchase an additional 675000 shares of common stock. As a result, the Company sold a total of 5175000 shares of its common stock at a price to the public of …
See all stories on this topic »